Market Overview

UPDATE: Bank of America Upgrades Vitamin Shoppe to Buy on Healthy and Sustainable Growth

Share:
Related VSI
Barclays Downgrades Vitamin Shoppe To Equal-weight
Benzinga's Top Downgrades

Bank of America raised its rating on Vitamin Shoppe (NYSE: VSI) from Neutral to Buy and upped its price objective from $65 to $67.

Bank of America noted, "VSI is a rare example of a recession-proof domestic growth story with ample square footage and international potential. Net income is forecast to grow by 25/20/19% from 2012-14 on the back of a 8%/6.5%/6.5% comp and ~9% square footage growth. Importantly, VSI's expected net income growth rate is nearly double that of its hardline peers (~10% per year from 2012-14E) which we believe will help support the company's premium multiple. In addition, with the company debt-free and net cash starting to mount, we believe share repurchases or a dividend could easily be accommodated despite its growth plans."

Vitamin Shoppe closed at $56.35 on Tuesday.

Latest Ratings for VSI

DateFirmActionFromTo
Feb 2015JefferiesMaintainsHold
Feb 2015BarclaysDowngradesOverweightEqual-weight
Nov 2014Goldman SachsDowngradesBuyNeutral

View More Analyst Ratings for VSI
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (VSI)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→